文献速递肝病消化道肿瘤与早癌

列线图预测肝细胞癌术后复发患者的生存

Nomogram to Predict Survival of Patients With Recurrence of Hepatocellular Carcinoma After Surgery.
PubMed 文献 · Clin Gastroenterol Hepatol · 2017-12-12

研究利用638例肝细胞癌根治性切除后复发患者数据建立预测复发后2年和5年生存的列线图,并在内部213例和外部127例队列中验证;列线图C指数0.797,高于巴塞罗那临床肝癌分期复发版的0.713,并能准确分层患者生存。

要点

  • 列线图基于抗病毒治疗、复发时白蛋白-胆红素分级和甲胎蛋白水平等变量预测复发后生存。
  • 训练队列C指数0.797(95%CI 0.765-0.830),高于巴塞罗那临床肝癌分期复发版的0.713(95%CI 0.680-0.745)(P<.001)。
  • 列线图将患者分为长期、中期和短期生存组,2年生存率分别为91.2%、67.6%和23.8%,5年生存率分别为74.9%、53.3%和9.1%。

核心结论

  • 建立并内部和外部验证了列线图,用于确定肝细胞癌根治性切除后复发患者在不同时间点的生存概率,多数患者有乙型肝炎病毒感染。

研究设计与样本

  • 训练队列为2007年至2013年中国广州中山大学肿瘤防治中心638例肝细胞癌根治性切除后复发患者,中位随访39.7个月。
  • 内部验证队列为同一机构213例患者,外部验证队列为中国2个其他中心127例患者,时间范围为2002年至2009年。

主要发现

  • 训练队列列线图预测生存的C指数为0.797(95%CI 0.765-0.830),高于巴塞罗那临床肝癌分期复发版的0.713(95%CI 0.680-0.745)(P<.001)。
  • 列线图将患者分为预测长期、中期和短期生存组,复发后2年生存比例分别为91.2%、67.6%和23.8%。
  • 列线图预测的复发后5年生存比例在长期、中期和短期生存组分别为74.9%、53.3%和9.1%。
  • 内部验证队列C指数为0.756(95%CI 0.703-0.808),外部验证队列C指数为0.747(95%CI 0.701-0.794)。

关键数值与推荐

  • 列线图基于与肝细胞癌复发后生存独立相关的变量,包括抗病毒治疗、复发时白蛋白-胆红素分级和甲胎蛋白水平、从初次切除到复发的时间、复发灶大小、部位、数目以及复发治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We aimed to establish and validate a nomogram to predict survival at 2 and 5 years after recurrence of hepatocellular carcinoma (HCC) in patients who have undergone curative resection. METHODS: We developed a nomogram using data from a training cohort of 638 patients (most with hepatitis B virus infection) with recurrence of HCC after curative resection at Sun Yat-sen University Cancer Center, in Guangzhou, China from 2007 through 2013. The median follow-up time was 39.7 months. Patients were evaluated every 3-4 months for the first 2 years after resection and every 3-6 months thereafter. The nomogram was based on variables independently associated with survival after HCC recurrence, including antiviral treatment; albumin-bilirubin grade and alpha-fetoprotein level at recurrence; time from primary resection to recurrence; size, site, number of recurrences; and treatment for recurrence. We validated the nomogram using data from an independent internal cohort of 213 patients treated at the same institution and an external cohort of 127 patients treated at 2 other centers in China, from 2002 through 2009. The predictive accuracy of the nomogram was measured using Harrell's concordance index (C index) and compared with the Barcelona Clinic Liver Cancer staging system of recurrence. RESULTS: Our nomogram predicted survival of patients in the training cohort with a C-index of 0.797 (95% CI, 0.765-0.830)-greater than that of the Barcelona Clinic Liver Cancer staging system for recurrence (C-index score, 0.713; 95% CI, 0.680-0.745) (P < .001). This nomogram accurately stratified patients into subgroups with predicted long, medium, and short survival times: the proportions of patients in each group who survived 2 years after HCC recurrence were 91.2%, 67.6%, and 23.8%; the proportions of patients in each group who survived 5 years after HCC recurrence were 74.9%, 53.3%, and 9.1%. Our nomogram predicted patient survival times with C-index scores of 0.756 (95% CI, 0.703-0.808) in the internal validation cohort and 0.747 (95% CI, 0.701-0.794) in the external validation cohorts. CONCLUSIONS: We developed a nomogram to determine the probability of survival, at different time points, of patients with recurrence of HCC (most with hepatitis B virus infection), after curative resection and validated it internally and externally.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. He W, Peng B, Tang Y, et al. Nomogram to Predict Survival of Patients With Recurrence of Hepatocellular Carcinoma After Surgery. Clin Gastroenterol Hepatol. 2017. PMID: 29246702. doi:10.1016/j.cgh.2017.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。